期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
扶正抑瘤汤对原发性肝癌根治切除术患者术后复发及血管肿瘤标志物水平的影响观察 被引量:2
1
作者 尹全金 王岩 +1 位作者 徐磊 李忠廉 《辽宁中医杂志》 CAS 2022年第8期133-135,共3页
目的观察扶正抑瘤汤对原发性肝癌根治切除术患者术后复发及血管肿瘤标志物水平的影响。方法纳入2016年1月—2017年12月收治的80例原发性肝癌根治术患者作为研究对象,应用电脑双盲法分为对照组和观察组,每组40例。两组患者均给予肝癌根... 目的观察扶正抑瘤汤对原发性肝癌根治切除术患者术后复发及血管肿瘤标志物水平的影响。方法纳入2016年1月—2017年12月收治的80例原发性肝癌根治术患者作为研究对象,应用电脑双盲法分为对照组和观察组,每组40例。两组患者均给予肝癌根治术进行治疗,术后对照组给予常规放化疗治疗,观察组则在对照组基础上给予扶正抑瘤汤进行治疗,两组患者均进行连续3年的随访,对其术后生存率、复发情况进行观察,同时观察两组治疗前后血管肿瘤标志物水平和治疗过程中不良反应发生情况。结果观察两组患者术后生存率及复发情况发现,两组患者术后1年和2年的生存率差异无统计学意义(P>0.05),术后3年观察组生存率高于对照组,且观察组术后复发率低于对照组,组间差异有统计学意义(P<0.05)。观察两组治疗前后血管肿瘤标志物水平发现,治疗前两组各指标间差异无统计学意义(P>0.05),治疗后观察组的AFP(甲胎蛋白)、CEA(外周血癌胚抗原)及DCP(人血清异常凝血酶原)均低于对照组,组间差异有统计学意义(P<0.05)。观察两组患者治疗过程中不良反应发生情况发现,观察组总发生率低于对照组,组间差异有统计学意义(P<0.05)。结论研究发现,扶正抑瘤汤在原发性肝癌根治切除术患者术后治疗中应用效果良好,可有效地延长患者生存期,降低术后复发风险,改善患者血管肿瘤标志物水平,提高临床治疗的有效性,同时还可减少患者治疗不良反应的发生,提高治疗安全性。 展开更多
关键词 扶正抑瘤汤 原发性肝癌 肝癌根治术 术后复发 血管肿瘤标志物水平
下载PDF
Tumor Vascular Markers: Possibilities for Detection of Breast Carcinoma
2
作者 Miroslava Bilecova-Rabajdova Peter Urban +3 位作者 Andrea Gresova Anna Birkova Alexander Ostro Maria Marekova 《Journal of Chemistry and Chemical Engineering》 2012年第2期118-123,共6页
Breast cancer is one of the world's most urgent health problems. The first symptoms of mammary malignancies are manifested only at an advanced stage with significant mortality. Detecting this disease at an early stag... Breast cancer is one of the world's most urgent health problems. The first symptoms of mammary malignancies are manifested only at an advanced stage with significant mortality. Detecting this disease at an early stage gives the majority of patients a better chance of survival. The aim was to search for changes in gene expression of specific tumor vascular markers like death receptor 6 (Dr6) and glycoprotein M6B (Gpm6B) in the blood of patients with breast cancer. All subjects were divided into two groups. First group with patients are with different grades of breats tumors (n = 30). Second group consists from healthy women (n = 15). After isolation of mRNA from blood, RT-PCR was followed by gel electrophoresis. For statistical analysis one-way ANOVA was used with Student's T test using GraphPad InStat software. Significant changes in mRNA levels of gene Dr6 in all grades of first stage breast cancer were detected. The mRNA levels of Dr6 showed a rising tendency from GI (116% higher value than control) to G3 (198% higher than control). During monitoring of the mRNA level of Gpm6B, a weaker increase was observed than in Dr6. The difference in GI was only 8% higher compared with controls and 44% at G3. From our results it can be concluded that DR6 is a more suitable marker for the diagnosis of breast malignancies in the early stages than Gpm6B. In our work, a non-invasive method for more timely and precise determination of the earlier stages of breast cancer is described, which could also contribute to monitoring the effectiveness of treatment, or regression of this disease. 展开更多
关键词 RT-PCR Dr6 Gpm6B gynecological malignancies breast cancer.
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部